Page 40 of 44

BMJ Open

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohortreporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Page

Reporting Item Number

Title and

abstract

Title #1a Indicate the study's design with a commonly used 1

term in the title or the abstract

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Page 41 of 44

. 5 .				
1 2 3 4 5 6 7 8 9	Abstract	<u>#1b</u>	Provide in the abstract an informative and	3-4
			balanced summary of what was done and what	
			was found	
	Introduction			
11 12 13	Background /	<u>#2</u>	Explain the scientific background and rationale for	6-7
14 15 16	rationale		the investigation being reported	
17 18	Objectives	<u>#3</u>	State specific objectives, including any	7
19 20			prespecified hypotheses	
21 22 23 24	Methods			
25 26	Study design	<u>#4</u>	Present key elements of study design early in the	8
27 28 29 30			paper	
31 32	Setting	<u>#5</u>	Describe the setting, locations, and relevant	8
33 34			dates, including periods of recruitment, exposure,	
35 36 37 38			follow-up, and data collection	
39 40	Eligibility criteria	<u>#6a</u>	Give the eligibility criteria, and the sources and	8
41 42			methods of selection of participants. Describe	
43 44 45 46 47			methods of follow-up.	
	Eligibility criteria	<u>#6b</u>	For matched studies, give matching criteria and	n/a (not a
48 49 50			number of exposed and unexposed	matched
51 52				study)
53 54 55	Variables	<u>#7</u>	Clearly define all outcomes, exposures,	8-9
56 57			predictors, potential confounders, and effect	
58 59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

			BMJ Open	Page 42 of 44
1 2 3 4 5 6 7 8 9 10			modifiers. Give diagnostic criteria, if applicable	
	Data sources /	<u>#8</u>	For each variable of interest give sources of data	8-9
	measurement		and details of methods of assessment	
			(measurement). Describe comparability of	
			assessment methods if there is more than one	
12 13 14			group. Give information separately for for	
14 15 16 17 18 19 20 21 22			exposed and unexposed groups if applicable.	
	Bias	<u>#9</u>	Describe any efforts to address potential sources	9-10
			of bias	
23 24 25	Study size	<u>#10</u>	Explain how the study size was arrived at	8
26 27	Quantitative	<u>#11</u>	Explain how quantitative variables were handled	11-12
28 29 30	variables		in the analyses. If applicable, describe which	
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58			groupings were chosen, and why	
	Statistical	<u>#12a</u>	Describe all statistical methods, including those	
	methods		used to control for confounding 11-12	
	Statistical	<u>#12b</u>	Describe any methods used to examine	11-12
	methods		subgroups and interactions	
	Statistical	<u>#12c</u>	Explain how missing data were addressed	8
	methods			
	Statistical	<u>#12d</u>	If applicable, explain how loss to follow-up was	n/a
	methods		addressed	
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

Page 43 of 44

1 2	Statistical	<u>#12e</u>	Describe any sensitivity analyses	n/a	
3	methods				
5 6					
7 8 9					
10 11 12 13	Results				
	Participants	<u>#13a</u>	Report numbers of individuals at each stage of		13
14 15 16			study—eg numbers potentially eligible, examined		
17 18			for eligibility, confirmed eligible, included in the		
19 20			study, completing follow-up, and analysed. Give		
21 22			information separately for for exposed and		
23 24 25			unexposed groups if applicable.		
26 27	D (1)	#40 1		40	
28 29 30 31	Participants	<u>#13b</u>	Give reasons for non-participation at each stage	13	
	Participants	<u>#13c</u>	Consider use of a flow diagram	13	
32 33				(Figure	
34 35 36				1)	
37 38					
39 40					
41 42	Descriptive data	<u>#14a</u>	Give characteristics of study participants (eg	13-15,	
43 44			demographic, clinical, social) and information on	Table 1	
45 46 47			exposures and potential confounders. Give		
48 49			information separately for exposed and		
50 51			unexposed groups if applicable.		
52 53	Descriptive data	#14b	Indicate number of participants with missing data	n/a	
54 55	2000.ip.i.vo data	<u># 1 10</u>	for each variable of interest	.,,	
56 57 58			To Guori variable of interest		
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xht	:ml	

BMJ Open

Page 44 of 44

			вив орен		ruge
1 2 3 4 5 6 7 8 9	Descriptive data	#14c	Summarise follow-up time (eg, average and total amount)	15	
11 12 13 14 15 16 17 18 19 20	Outcome data	<u>#15</u>	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.	13-17	
21 22 23 24 25 26 27 28 29 30 31 32 33	Main results	<u>#16a</u>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17-18	
34 35 36 37 38 39	Main results	<u>#16b</u>	Report category boundaries when continuous variables were categorized	17-18	
40 41 42 43 44 45 46 47 48 49	Main results	#16c	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/a	
50 51 52 53 54 55 56 57 58 59 60	Other analyses	#17 For pe	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses er review only - http://bmjopen.bmj.com/site/about/guidelines.xht	17-18	

Page 45 of 44	BMJ Open

1 2 3	Discussion					
4 5 6 7 8 9 10	Key results	<u>#18</u>	Summarise key results with reference to study	19		
			objectives			
	Limitations	<u>#19</u>	Discuss limitations of the study, taking into	23-24		
12 13			account sources of potential bias or imprecision.			
14 15			Discuss both direction and magnitude of any			
16 17 18			potential bias.			
19 20	Interpretation	<u>#20</u>	Give a cautious overall interpretation considering	19-23		
21 22 23			objectives, limitations, multiplicity of analyses,			
24 25			results from similar studies, and other relevant			
26 27 28			evidence.			
29 30 31	Generalisability	<u>#21</u>	Discuss the generalisability (external validity) of	22-23		
32 33			the study results			
34 35 36	Other					
37 38 39	Information					
40 41	Funding	<u>#22</u>	Give the source of funding and the role of the	1		
42 43			funders for the present study and, if applicable,			
44 45			for the original study on which the present article			
46 47 48 49 50			is based			

None The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml